Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women With Low Bone Mineral Density

NCT00377819 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00377819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00377819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women With Low Bone Mineral Density
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2006
Completion date
July 31, 2008
Enrollment
504 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal osteoporosis